Figure 2 Survival curves in the elderly vs. younger patients

Slides:

Advertisements

Similar presentations

Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies by Lawrence de Koning,

Advertisements

The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH by Antigone.

Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial by Atul Verma, Roberto Mantovan,

Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter by Lluís Mont, Roberto Elosua, and Josep Brugada Europace Volume 11(1):11-17.

Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay:

The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator by Guiqing Yao, Nick Freemantle,

Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis by David C. Burgess, Michael.

The combined influence of leisure-time physical activity and weekly alcohol intake on fatal ischaemic heart disease and all-cause mortality by Jane Østergaard.

Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome by Andrea Sarkozy, Tim Boussy, Georgios.

Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty:

One year follow-up after cryoballoon isolation of the pulmonary veins in patients with paroxysmal atrial fibrillation by Yves Van Belle, Petter Janse,

Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary bypass grafting: a prospective, double-blinded, placebo-controlled,

Short stature is associated with coronary heart disease: a systematic review of the literature and a meta-analysis by Tuula A. Paajanen, Niku K.J. Oksala,

Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Comparative Effectiveness of Rhythm Control vs Rate.

Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction †

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Beta-Blockers and Outcome in Heart Failure and Atrial.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

Delivery of care for adult patients with congenital heart disease in Europe: results from the Euro Heart Survey by Philip Moons, Peter Engelfriet, Harald.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk Assessment and Comparative Effectiveness of.

Prognostic value of coronary artery calcium screening in asymptomatic smokers and non-smokers by Leslee J. Shaw, Paolo Raggi, Tracy Q. Callister, and Daniel.

Date of download: 6/25/2016 Copyright © 2016 American Medical Association. All rights reserved. From: BNP-Guided vs Symptom-Guided Heart Failure Therapy:

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Transition of Patients From Blinded Study Drug to.

Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation.

Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38.

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Evidence That D-Dimer Levels Predict Subsequent.

Imaging and atrial fibrillation: the role of multimodality imaging in patient evaluation and management of atrial fibrillation by Laurens F. Tops, Martin.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Gastrointestinal Bleeding in Patients With Atrial.

High heart rate: a cardiovascular risk factor? by Stéphane Cook, Mario Togni, Marcus C. Schaub, Peter Wenaweser, and Otto M. Hess EHJ Volume 27(20):

Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.

Figure 2. CONSORT flow diagram.

From: Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial Fibrillation Ann Intern Med. 2007;147(8): doi: /

Figure 1 Flow diagram displaying the proportions of patients with troponin measurements available from all eligible patients and the resulting study population.

Figure 1 Ischaemic endpoints

Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.

Figure 1 Patient flow chart.

Copyright © 2012 American Medical Association. All rights reserved.

Figure 2 Kaplan–Meier estimates of event-free survival (survival to the combined endpoint). From: Long-term outcomes of patients with acute myocardial.

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

Figure 1 Flow chart diagram of high-risk group AF patients

Figure 2 The incidence of new onset AF, strokes, heart failure, and mortality according to the BMI (/ person-years). (Left: BMI

Figure 2 Lack of changes in current properties between myocytes

Figure 1 The flowchart depicts the total number of procedures in the Western Denmark Heart Registry (WDHR) and the exclusion of patients; NPR, National.

Figure 1. Nonadherence to guidelines for prescribing antiplatelet and anticoagulant therapy in 144 patients with atrial fibrillation who attend a Spanish.

Figure 1 Flow chart of study selection.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1 Incidence and total numbers of SCD in patients with depressed LV systolic function and in patients with preserved LV function. The incidence of.

Figure 1 Study flow chart

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal Gregory.

Randomized Evaluation of Long-term anticoagulant therapY

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

Figure 1 Patient selection flow chart

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.

Figure 1 Overall lag-cumulative exposure–response relationships between air temperature and myocardial infarction ... Figure 1 Overall lag-cumulative exposure–response.

Figure 9 Management of atrial fibrillation

Figure 1 Relationships between magnitude of antithrombotic benefit vs

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Take home figure The 38% of heart failure reduced ejection fraction (HFrEF) patients who recovered LVEF (HFrecEF) were more ... Take home figure The 38%

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Patient selection

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Figure 1 Patient selection.

Gianluigi Savarese et al. JCHF 2016;4:

Presentation transcript:

Figure 2 Survival curves in the elderly vs. younger patients Figure 2 Survival curves in the elderly vs. younger patients. (A) Outcome. (B) Severe bleeding events. SE, standard error; n, number of ITT patients at risk. From: Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial Eur Heart J. 2006;28(8):996-1003. doi:10.1093/eurheartj/ehl364 Eur Heart J | © The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Figure 3 Relative effect on vascular events. (A) The elderly vs Figure 3 Relative effect on vascular events. (A) The elderly vs. younger group. (B) Combined vs. anticoagulant therapy. The hazard ratio (HR) = logarithm hazard ratio whose 95% (error bars) excludes the vertical line are statistically significant at the 5% level. From: Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial Eur Heart J. 2006;28(8):996-1003. doi:10.1093/eurheartj/ehl364 Eur Heart J | © The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Figure 4 Outcome survival curves during combined and anticoagulant therapy. (A) The elderly patients. (B) Younger patients. n, ITT patients at risk. From: Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial Eur Heart J. 2006;28(8):996-1003. doi:10.1093/eurheartj/ehl364 Eur Heart J | © The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Figure 1 Flow chart of NASPEAF patients Figure 1 Flow chart of NASPEAF patients. ITT corresponds to patients of whom efficacy and safety data are available. IQR<sub>P25–P75</sub>, interquartile range; anticoagulant therapy, INR range of 2.0–3.0. Combined therapy, triflusal 600 mg/day plus anticoagulation for a median INR of 1.97–2.17. From: Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial Eur Heart J. 2006;28(8):996-1003. doi:10.1093/eurheartj/ehl364 Eur Heart J | © The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org